Tempest Therapeutics
TPST
84 hedge funds and large institutions have $31.7M invested in Tempest Therapeutics in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 16 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
5% more funds holding
Funds holding: 80 → 84 (+4)
85% less capital invested
Capital invested by funds: $206M → $31.7M (-$175M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $38K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.77M |
| 2 |
Millennium Management
New York
|
+$1.57M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$1.32M |
| 4 |
Morgan Stanley
New York
|
+$473K |
| 5 |
AIC
AWM Investment Company
New York
|
+$424K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$18.9M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$16.4M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$12.1M |
| 4 |
Jennison Associates
New York
|
-$3.31M |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$2.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMG
101
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$125K | -6 | Closed |
|
102
Marshall Wace
London,
United Kingdom
| – | -$79K | -4 | Closed |
|
|
QIM
103
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$80K | -4 | Closed |
|
104
SG Americas Securities
New York
| – | -$74K | -4 | Closed |
|
|
AC
105
Amici Capital
New York
| – | -$72K | -3 | Closed |
|
|
MLM
106
Mount Lucas Management
Newtown,
Pennsylvania
| – | -$34K | -2 | Closed |
|
107
JP Morgan Chase
New York
| – | -$9K | – | – |
|
TPST Hedge Fund Activity: Q4 2016 in Review
84 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2016, worth a combined $31.7M — down 85% from $206M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TPST positions and 16 closed out — a net gain of 4 holders — while 21 added to existing stakes and 13 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.77M. The largest seller was Orbis Allan Gray, exiting entirely with an estimated $18.9M sold.
- 84 institutional investors held Tempest Therapeutics (TPST) as of Q4 2016, up from 80 in Q3 2016.
- Funds reported $31.7M of Tempest Therapeutics stock for Q4 2016, down 85% quarter-over-quarter.
- 20 funds opened new Tempest Therapeutics positions in Q4 2016 and 16 closed out, a net change of +4 holders.
- The largest Tempest Therapeutics buyer in Q4 2016 was Anson Funds Management, an estimated $1.77M added.
- The largest Tempest Therapeutics seller in Q4 2016 was Orbis Allan Gray, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2016.